Brief: Syros Receives Fast Track Designation From FDA For Tamibarotene

Syros Pharmaceuticals

09/04/2024 12:23

April 9 (Reuters) - Syros Pharmaceuticals Inc  SYRS.O :
    * SYROS RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR
TAMIBAROTENE FOR THE TREATMENT OF NEWLY DIAGNOSED UNFIT AML WITH
RARA GENE OVEREXPRESSION
    * SYROS PHARMACEUTICALS INC: EXPECTS TO REPORT ADDITIONAL
DATA
FROM SELECT-AML-1 IN 2024

Source text for Eikon:  ID:nBwMQZxna 
Further company coverage:  SYRS.O 

 ((Reuters.Briefs@thomsonreuters.com;))